Bleeding News and Research

RSS

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Michigan hospitals face rising costs; Doctor urges culture changes to increase safety

Hospitals in Michigan are losing money, according to a report expected to be released today by the Michigan Health & Hospital Association. The Detroit Free Press reports that the losses are leading to "layoffs, hiring freezes and elimination of some services."

2 Mar 2010

Bayer HealthCare Pharmaceuticals' RECOTHROM solution receives Health Canada approval

Bayer HealthCare Pharmaceuticals announced today that RECOTHROM(R) (Thrombin alfa (Recombinant)), the first recombinant, plasma-free thrombin approved by Health Canada, is now available for use as a topical hemostatic solution. According to a recent clinical study, RECOTHROM(R) was found to successfully stop 80 per cent of surgical bleeding within three minutes and 95 per cent of bleeding within 10 minutes.

1 Mar 2010

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, but the effectiveness does vary by age, say researchers at the University of Alabama at Birmingham in collaboration with other North American stroke investigators.

1 Mar 2010

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

A major study shows that a minimally-invasive procedure is as effective and safe as the gold standard for treating blockages of the carotid artery, giving patients who prefer a less invasive procedure a proven alternative.

27 Feb 2010

Stroke incidence and treatment: Racial and geographic disparities

Blacks are more likely to have an undiagnosed key risk factor for stroke and are more likely to have a stroke than whites, according to two studies presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

For people who carry common gene variants, smoking increases risk of aneurysm

For people who carry common gene variants, cigarette smoking greatly increases the risk that a blood vessel in the brain will weaken and balloon out - called an aneurysm - which could be life-threatening if it ruptures, according to research presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

With the realization that half of the people experiencing a sudden mortal heart attack were taking aspirin on the day of their demise, and the fact that higher-than-recommended doses of aspirin are needed to prevent blood clot formation in coronary arteries, coupled with an announcement that the red wine molecule resveratrol (rez-vair-ah-trawl) may protect from sudden mortal heart attack in a superior fashion to aspirin, suggests re-evaluation of cardiology's current instruction regarding prevention of heart attacks, says Nate Lebowitz MD, cardiologist with the Advanced Cardiology Institute in Ft. Lee, New Jersey.

26 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Platelet function tests may predict heart attack, says study

An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a coronary stent implantation found that only three of the tests were associated with a modest ability to predict outcomes such as heart attack or death, according to a study in the February 24 issue of JAMA.

25 Feb 2010

Patients with unwitnessed strokes may benefit from clot-busting drugs

Clot-busting treatment should be considered for patients last seen healthy within a few hours before having a stroke, according to research presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Synovis Life Technologies reports net revenue of $15.2M for first-quarter fiscal 2010

Synovis Life Technologies, Inc., today reported financial results for the first fiscal quarter ended Jan. 31, 2010.

24 Feb 2010

Smith & Nephew launches DYONICS RF System to remove soft tissue during arthroscopic surgery

Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.

24 Feb 2010

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

Medical device company Vertos Medical Inc. has reported that an observational study on mild, published in the January/February 2010 issue of the peer-reviewed journal Pain Physician, has demonstrated the acute safety of the procedure in the treatment of lumbar spinal stenosis (LSS).

24 Feb 2010

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world. To date, NCC has received more than 10 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment. The value of this donation is more than $13 million, and it will help many hundreds of hemophilia patients around the world.

23 Feb 2010

Heartware completes patient enrollment for ADVANCE clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced the conclusion of patient enrollment under its "ADVANCE" clinical trial.

23 Feb 2010

Bleeding after percutaneous biopsy rare

Even among patients who have taken aspirin in proximity to an image-guided percutaneous biopsy, risk of major bleeding associated with the procedure is low, according to a study in the March issue of the American Journal of Roentgenology (www.ajronline.org). Image-guided percutaneous biopsies are an important means of diagnosing disease in organs and other soft tissues. They involve the removal of cells or tissues for examination.

20 Feb 2010

Bleeding News and Research

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Michigan hospitals face rising costs; Doctor urges culture changes to increase safety

Bayer HealthCare Pharmaceuticals' RECOTHROM solution receives Health Canada approval

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

Stroke incidence and treatment: Racial and geographic disparities

For people who carry common gene variants, smoking increases risk of aneurysm

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Platelet function tests may predict heart attack, says study

Patients with unwitnessed strokes may benefit from clot-busting drugs

Synovis Life Technologies reports net revenue of $15.2M for first-quarter fiscal 2010

Smith & Nephew launches DYONICS RF System to remove soft tissue during arthroscopic surgery

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

Heartware completes patient enrollment for ADVANCE clinical trial

Bleeding after percutaneous biopsy rare

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News